Hyperpyrexia in life-threatening central nervous system infection – It is the timepoint of fever which matters: A plea to select the best timing and optimal methods of temperature management

Schmutzhard Erich, Pfausler Bettina

Since Hippokrates’ times, it has been known that fever and even more, hyperpyrexia in a potentially fatally ill neurocritical care patients, in particular in severe central nervous system (CNS) infections is detrimental, heralding poor prognosis, and adding to morbidity and mortality. It is the timepoint of fever which matters: A plea to select the best timing and optimal methods of temperature management

Since Hippokrates’ times, it has been known that fever and even more, hyperpyrexia in a potentially fatally ill neurocritical care patients, in particular in severe central nervous system (CNS) infections is detrimental, heralding poor prognosis, and adding to morbidity and mortality. It is the timepoint of fever which matters: A plea to select the best timing and optimal methods of temperature management.

In patients suffering from impaired consciousness due to ABM, up to two-thirds show increased ICP when measured early. Aggressive reduction of this increased ICP has been shown to reduce mortality from 30% to 10%. In bacterial meningitis, beside diffuse brain edema, hyperemia of brain areas and secondary disturbance of microcirculation within the affected intracranial structures leading to, highly impaired arterial/arteriolar microcirculation, as well as partially occluded/thrombosed venules/venous vasculature add to increased ICP with the potential of severe secondary damage of brain tissue.

Whereas in the early phase of acute infectious disease of the meninges and the brain tissue, the pathogen plays the key role in maintaining and aggravating infection and inflammation as evidenced by PET- and microdialysis studies in viral and bacterial infections of the brain, it will be the secondary damages throughout the course of the infectious CNS disease which add substantially to morbidity and mortality.

Antimicrobial chemotherapy is given with the aim to kill the causative pathogens as quickly and as early as possible. It is exactly

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
during the early phase of the disease when the brain reacts toward the rapidly multiplying pathogens with what recently has been called “Pathogen Associated Molecular Pattern” (PAMP). It seems logical and essential that the rapidly multiplying pathogens provoke a widespread and immunological host reactions, fever being only the visible tip of the “iceberg” of them. Therefore, the foremost aim at this, early, stage of disease must be to constrain the causative pathogens (e.g., Streptococcus pneumoniae – pneumococci) and to reduce the overwhelming immune reaction, as it is done in case of ABM.\textsuperscript{[5,10,11]} In a patient suffering from pneumococcal ABM, the early combination of bactericidal or-lytic antibiotics (e.g., third-generation cephalosporin) with a 4-day- course of dexamethasone improves outcome.\textsuperscript{[5,10,11]} If, however, steroids are given to a comatose pneumococcal ABM patient too late, or in a prolonged way, the positive effects might be even reversed.\textsuperscript{[10,11]} Liston and Masters have clearly shown that during the later course of life-threatening ABM it is the then Damage Associated Molecular Pattern (mechanisms) (DAMP) which plays the pivotal, more crucial, more important role.\textsuperscript{[9]} This DAMP, i.e., largely damaged neuronal cells, provoke a different upregulation of immune responses, with fever or even hyperpyrexia.\textsuperscript{[12,13]} The secondary damages of ABM are aggravated by this hyperpyrexia\textsuperscript{[11,12]} and by secondary oxygen and nutrition deprivation of already partially damaged neuronal cells.\textsuperscript{[12-14]}

Taking these two completely different types of fever into account, it seems all too logical that in the early phase of ABM moderate therapeutic hypothermia (TH) by physical means might be detrimental, this fact has been shown recently to hold true in practice in the French ABM-hypothermia study.\textsuperscript{[15]} The results of this prospective randomized controlled French ABM-hypothermia study suggest a detrimental effect of moderate hypothermia when given during the first 24 h of ABM. In these French patients, dexamethasone was administered rather late (up to 5 h after the first dose of antibiotic), and even more importantly, the moderate TH (33°C–34°C) (applied for the first 24 h) patients were withheld antipyretic pharmacotherapy, which – in contrast – was given liberally and as deemed necessary by the treating intensivist, to the “normothermic” patients’ group.\textsuperscript{[15]} It clearly might be reasoned that during the acute ABM phase, i.e., when PAMP most matter, antipyretics might even increase the beneficial effect of steroids as long as their potential negative side effects are monitored for and appropriately taken care for. However, it seems equally logical that during the later phase of the ABM, when the DAMP eventually prevails and leads to a tilt of the delicate immunological homeostasis. This so-called Homeostasis Associated Molecular Pattern (HAMP), adding to secondary brain/neuronal cell damage, might even more benefit from TH or, at least, targeted temperature management (TTM). Not controlling the body temperature after TH might have contributed to secondary brain/neuronal cell damage.\textsuperscript{[11,12]} Therefore, it is safe to assume that continuing TTM could save such partially damaged and functionally impaired neuronal cells over the critical period of ABM, i.e., far beyond the first 24 h. This potential to improve the devastating outcome was clearly missed in this patients’ group.

In view of this recently proposed concept of PAMP – DAMP – HAMP,\textsuperscript{[9]} we suggest to test, both in animal and in comatose patients with severe acute bacterial (preferably pneumococcal) meningitis and viral encephalitis the concept of differentiated temperature management throughout the course of disease. In the early phase, i.e., within 24–72 h, “aggressive” administration of antipyretics should supplement the steroid and antibiotic therapies. In the later course (beyond day 4) in every patient, still suffering from increased ICP, brain edema, arterial, or venous complications normothermia should be aimed at and meticulously maintained – by all means – until the clinical, monitoring, and neuroimaging evolution suggests that DAMP and HAMP have been overcome.

References

1. Diringer MN, Neurocritical Care Fever Reduction Trial Group. Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system. Crit Care Med 2004;32:559-64.
2. Broessner G, Lackner P, Fischer M, Beer R, Helbok R, Pfausler B, et al. Influence of prophylactic, endovascularly based normothermia on inflammation in patients with severe cerebrovascular disease: A prospective, randomized trial. Stroke 2010;41:2969-72.
3. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: Spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003;126:1015-25.
4. Glimäker M, Johansson B, Halldorsdottir H, Wanecek M, Elmi-Terander A, Ghatan PH, et al. Neuro-intensive treatment targeting intracranial hypertension improves outcome in severe bacterial meningitis: An intervention-control study. PLoS One 2014;9:e91976.
5. de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56.
6. Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin 2018;34:63-80.
7. Dietmann A, Putzer D, Beer R, Helbok R, Pfausler B, Nordin AJ, et al. Cerebral glucose hypometabolism in tick-borne encephalitis, a pilot study in 10 patients. Int J Infect Dis 2016;51:73-73.
8. Kofler M, Schiefecker A, Beer R, Sohn F, Broessner G, Rhomberg P, et al. Neuroglucopenia and metabolic distress in two patients with viral meningencephalitis: A Microdialysis study. Neurocrit Care 2016;25:273-81.
9. Liston A, Masters SL. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat Rev Immunol 2017;17:208-14.
10. van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: Guidance and challenges. Clin Microbiol Infect 2017;23:601-6.
11. van de Beek D, de Gans J. Dexamethasone and pneumococcal meningitis. Ann Intern Med 2004;141:327.
12. Provencio JJ, Badjatia N, Participants in the International Multi-disciplinary Consensus Conference on Multimodality Monitoring. Monitoring inflammation (including fever) in acute brain injury. Neurocrit Care 2014;21 Suppl 2:S177-86.
13. Scaravilli V, Tinchero G, Citerio G, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Fever management in SAH. Neurocrit Care 2011;15:287-94.
14. Schiefecker AJ, Beer R, Broessner G, Kofler M, Schmutzhard E, Helbok R, et al. Can therapeutic hypothermia be guided by advanced neuromonitoring in neurocritical care patients? A Review. Ther Hypothermia Temp Manag 2015;5:126-34.
15. Mourvillier B, Tubach F, van de Beek D, Garot D, Pichon N, Georges H, et al. Induced hypothermia in severe bacterial meningitis: A randomized clinical trial. JAMA 2013;310:2174-83.